Summary of canakinumab
Canakinumab is an anti-inflammatory drug. It inhibits the effects of the inflammatory mediator interleukin-1. It is only available as injections, which have to be taken every 8 weeks. Canakinumab may not available in every country.
Canakinumab is an anti-inflammatory drug
Canakinumab (it is pronounced ka-na-kee-nu-map) is an anti-inflammatory drug. Its brand name is Ilaris. Canakinumab inhibits the effects of the inflammatory mediator interleukin-1 (IL-1). This inflammatory mediator causes the signs and symptoms of autoinflammatory diseases.
IL-1 causes signs and symptoms of autoinflammation
IL-1 is an inflammatory mediator produced by certain white blood cells. These white blood cells are part of the so called innate immune system. IL-1 causes inflammatory signs and symptoms, such as fever, abdominal pain, muscle and joint pain and skin rash. Other inflammatory symptoms can also be caused by circulating IL-1.
The symptoms and signs of inflammation arise when IL-1 binds to its receptor. A receptor is a protein located on the outside of the cell membrane. When IL-1 binds to this protein, a signal is transmitted into the cell, leading to a cascade of reactions resulting in inflammation.
Anakinra inhibits inflammation by binding the IL-1 receptor
Anakinra is ... Read more »